First Nasal Spray for Anaphylaxis Approved by FDA

“Neffy,” the first nasal spray for treating anaphylaxis in an emergency, was authorised by the FDA. With this permission, treating severe allergic responses will be greatly aided and an alternative to regular epinephrine injections will be provided.

Anaphylaxis is a serious allergic reaction that can be fatal and has to be treated right away. Injections of adrenaline have historically been the only available therapy. But injection-related anxiety and reluctance, particularly in younger patients, have frequently prevented prompt medical attention. Consumers now have a needle-free alternative with neffy.

Kelly Stone, MD, PhD, Associate Director of the Division of Pulmonology, Allergy and Critical Care in the FDA’s Center for Drug Evaluation and Research stated: “Today’s approval provides the first epinephrine product for the treatment of anaphylaxis that is not administered by injection.”

She continued: “The availability of epinephrine nasal spray may reduce barriers to rapid treatment of anaphylaxis.”

Neffy is a nasal spray that is applied once to a single nostril. A fresh spray may be used in each nostril for a second dosage if symptoms do not get better or worsen. It is anticipated that this simplicity of usage would promote quicker emergency care.